Roadshow Project Registration

Displaying 44 - 45 of 46
Contact Name
Yechin Zhao
Contact Email
yechin.zhao@thronebio.com
Contact Phone Number
(630) 470-0034
Supplemental information (You may upload your business plan here.)
Your comment (optional)
Contact Job Title
Director of Strategic Business Development
Company Name
Throne Biotechnologies
Where is your company registered? (City, State, Country)
Delaware, United States
When was the company founded (year only)?
2011
Please choose the best keyword to describe your company/project?
RNA, Peptide & Gene Therapy / Stem Cells / Cellular Therapy
If you choose "Other" on the previous question, please enter your answer here:
Please choose the best choice from below to describe your company/project
Phase II
From which SAPA chapter did you learn about this roadshow event? (Please specify the referrer's name)
Other
If you choose "Other" on the previous question, please enter your answer here:
Direct referral by Dr. Xiao Dong Chen - Elect President of SAPA
Founder(s) and Management Team
Yong Zhao, MD, PhD, Founder, President
Dr. Yong Zhao is an internationally acclaimed scientist, immunologist, and former physician. Dr. Zhao is the inventor of 9 patents and has authored more than 52 peer-reviewed articles. His work has been celebrated by major news networks and global heads of states.

Gerald Ostrov, MBA - Director
Mr. Ostrov was the former Chairman at Johnson & Johnson. He has served as a senior executive to major health organizations including Novartis, Bausch & Lomb, and Proctor and Gamble. He received his MBA from Harvard.

Henry Lozano - Vice President of Global Relation
Mr Lozano was the former Deputy Assistant to the President of the United States. Mr. Lozano is an accomplished international business executive with an expanse network of diplomatic partners.

Yechin Zhao MBA(c) - Director of BD
Yechin is an experience entrepreneur with a trackrecord of global successes. He was an innovation consultant to Fortune 500 companies such as McDonalds and Disney
What is your core business?
We are an American therapeutic company with a disruptive stem cell technology that can fundamentally reverse diabetes, alopecia areata and other autoimmune diseases through immune education. Our patented technology is recognized as the leading “practical cure project” for type 1 diabetes out of 594 global projects (JDCA 2020). Stem Cell Educator therapy is a single dialysis-like, in vitro treatment that “resets” a patient’s immune system and correct the root issue behind the autoimmune disease.
What is the value and innovation of your core business?
Our technology, Stem Cell Educator Therapy, is an "immune system reset" that is designed to reverse diabetes and autoimmune diseases at the root level. Autoimmune disease occurs because of a defective immune system. Educator Therapy uses a newly discovered stem cell from the umbilical cord blood to reprogram one’s immune cells through an in-vitro process very similar to dialysis. The one time treatment is 8 hours long with virtually no side effects. We've done 10 years of laboratory and clinical research in Spain, China, and US. 200+ patients between the ages of 3 and 70 have received the treatement demonstrating safety and efficacy. The product is ready to use and waiting for FDA commercial approval (phase 2 approved for type 1 diabetes and alopecia areata).
What is your target market and what is the potential market size?
Type 1 Diabetes - 1.6 M people in US
Alopecia Areata - 6.8 M people in US
What are your risks and who are your competitors?
Viacyte, Caladrius, Mesoblast, Vertex
What is your project’s IP position?
Portfolio of 4 granted patents and 2 pending - Coverage in 10 global territories
What is your development plan for the next 3-5 years?
Series A Funding completed in 2021
FDA phase 2 completion beginning 2022
FDA phase 3 completion 2023
FDA approval 2024 International commercialization
How much fund have you raised so far? From which investor(s)?
11.4M from Angel investors, foundations, government grants, licenses, and donations.
What investment amount are you seeking?
$10M
$3M to complete phase 2 clinical trials
Description of the Project
Our technology, Stem Cell Educator Therapy, is an "immune system reset" that is designed to reverse diabetes and autoimmune diseases at the root level. Autoimmune disease occurs because of a defective immune system. Educator Therapy uses a newly discovered stem cell from the umbilical cord blood to reprogram one’s immune cells through an in-vitro process very similar to dialysis. The one time treatment is 8 hours long with virtually no side effects. We've done 10 years of laboratory and clinical research in Spain, China, and US. 200+ patients between the ages of 3 and 70 have received the treatement demonstrating safety and efficacy. The product is ready to use and waiting for FDA commercial approval (phase 2 approved for type 1 diabetes and alopecia areata).
If you choose "Other" on the previous question, please enter your answer here:
Company website
Thronebio.com
Entry ID
23
Sequence Number
45